A Meta-Analysis on the Long-Term Impact of Cytoreductive Surgery Plus HIPEC for Ovarian Cancer with Peritoneal Metastasis: Are We on the Right Path?
CRS plus HIPEC shows a favorable signal for OS and PFS in the limited HR-eligible evidence and appears feasible, with a pooled severe complication rate of ~18% and high CC-0 rates. Current data support HIPEC primarily as a targeted intensification strategy in carefully selected patients, while broader adoption requires additional randomized, context-specific evidence.
Authors
- Dan Alin Brebu
- Andreea-Adriana Neamțu (ORCID: https://orcid.org/0000-0002-5219-5466)
- Ionuţ Flaviu Faur (ORCID: https://orcid.org/0000-0001-6451-7461)
- Mircea Șelaru
- Danau Răzvan
Institutions
- Carol Davila University of Medicine and Pharmacy (RO)
- Clinical Emergency Hospital Bucharest (RO)
- Arad County Clinical Hospital (RO)
- Victor Babeș University of Medicine and Pharmacy Timișoara (RO)
Publication Details
- Journal
- Life
- Published
- 2026-02-14
- DOI
- https://doi.org/10.3390/life16020335
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 0.00